Corticotropin releasing factor data

NTII announced pilot Phase I/II trial results in 6 patients. The agent was given three times a day for three days in the open label, dose escalation study. Five of six patients were evaluated and all had reductions in painful tender joint counts and swollen joint counts, and improvement in both patient and physician global assessments. ...